Innate Pharma SA, a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. It offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas; Monalizumab, a checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications, as well as in Phase I/II clinical trial for the treatment of solid tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone33-04-30-30-30-30
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$110.96 million
Profitability
Miscellaneous
Employees195
Next Earnings DateN/A
OptionableNot Optionable
Innate Pharma (OTCMKTS:IPHYF) Frequently Asked Questions
What is Innate Pharma's stock symbol?
Innate Pharma trades on the OTCMKTS under the ticker symbol "IPHYF."
What price target have analysts set for IPHYF?
1 brokers have issued twelve-month target prices for Innate Pharma's stock. Their forecasts range from $11.00 to $11.00. On average, they anticipate Innate Pharma's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 71.7% from the stock's current price. View Analyst Price Targets for Innate Pharma.
What is the consensus analysts' recommendation for Innate Pharma?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innate Pharma.
Has Innate Pharma been receiving favorable news coverage?
Media headlines about IPHYF stock have trended positive this week, InfoTrie reports. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Innate Pharma earned a news impact score of 2.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the immediate future. View News Stories for Innate Pharma.
Who are some of Innate Pharma's key competitors?
Some companies that are related to Innate Pharma include Nabriva Therapeutics (NBRV), G1 Therapeutics (GTHX), Corcept Therapeutics (CORT), Insmed (INSM), Heron Therapeutics (HRTX), Supernus Pharmaceuticals (SUPN), Enanta Pharmaceuticals (ENTA), Madrigal Pharmaceuticals (MDGL), Deciphera Pharmaceuticals (DCPH), Ironwood Pharmaceuticals (IRWD), Ra Pharmaceuticals (RARX), Phibro Animal Health (PAHC), Aimmune Therapeutics (AIMT), Theravance Biopharma (TBPH) and Gossamer Bio (GOSS).
What other stocks do shareholders of Innate Pharma own?
Who are Innate Pharma's key executives?
Innate Pharma's management team includes the folowing people:
- Dr. Hervé Brailly, Co-Founder & Chairman of Supervisory Board (Age 58)
- Dr. Mondher Mahjoubi, Chairman of Exec. Board & CEO (Age 61)
- Mr. Yannis Morel, Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board (Age 46)
- Ms. Laure-Hélène Mercier, Exec. VP, CFO & Member of Exec. Board (Age 41)
- Mr. Eric Vivier D.V.M., Ph.D., Sr. VP & Chief Scientific Officer (Age 55)
How do I buy shares of Innate Pharma?
Shares of IPHYF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innate Pharma's stock price today?
One share of IPHYF stock can currently be purchased for approximately $6.4080.
How big of a company is Innate Pharma?
Innate Pharma has a market capitalization of $369.10 million and generates $110.96 million in revenue each year. The company earns $3.60 million in net income (profit) each year or $0.06 on an earnings per share basis. Innate Pharma employs 195 workers across the globe.View Additional Information About Innate Pharma.
What is Innate Pharma's official website?
How can I contact Innate Pharma?
Innate Pharma's mailing address is 117 AVENUE DE LUMINY - BP 30191, MARSEILLE I0, 13009. The company can be reached via phone at 33-04-30-30-30-30 or via email at [email protected]
MarketBeat Community Rating for Innate Pharma (OTCMKTS IPHYF)
MarketBeat's community ratings are surveys of what our community members think about Innate Pharma and other stocks. Vote "Outperform" if you believe IPHYF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPHYF will underperform the S&P 500 over the long term. You may vote once every thirty days.
